Beth Snyder BulikSenior EditorAs fatty liver disease gets a new name, will it also finally get approved drug treatments? That’s what healthcare professionals are hoping for as nonalcoholic fatty liver disease (NAFLD) becomes metabolic dysfunction-associated fatty liver disease (MAFLD), and nonalcoholic steatohepatitis (NASH) becomes metabolic dysfunction-associated steatohepatitis (MASH). The name changes, aimed at getting rid...
Tag: <span>Semaglutide</span>
Post
Novo Nordisk’s oral semaglutide on par with injectable version in weight loss and safety
June 25, 2023 10:39 PM EDTUpdated 05:32 AM R&DNovo Nordisk’s oral semaglutide on par with injectable version in weight loss and safetyKatherine LewinNews ReporterAn oral version of Novo Nordisk’s semaglutide helped patients taking the highest dose lose 15% of their body weight, the company reported in a new update. It’s on par with Novo’s Wegovy,...
Post
Semaglutide: Beware of buying the weight-loss drug online
by Margaret Steele, The Conversation The drug in Wegovy was inspired by the venom of the endangered Gila monster. Credit: Kunal Mehta/Shutterstock A few years ago, celebrity weight-control practices were out of most people’s reach. Live-in chefs and personal trainers, not to mention elaborate surgical procedures like the Brazilian butt lift, were not real options for...
Post
Could Semaglutide Treat Addiction as Well as Obesity?
Marlene Busko June 13, 2023 Could glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide — approved as Ozempic to treat type 2 diabetes and as Wegovy to treat obesity, both from Novo Nordisk — also curb addictions and compulsive behaviors? As demand for semaglutide for weight loss grew following approval of Wegovy by the US Food and Drug Administration in 2021, anecdotal reports of...
Post
Semaglutide 2.4 mg reduces CMDS score in patients with obesity
A late-breaking abstract was released today on a study in which patients were given a higher dose (2.4 mg) of semaglutide than is currently approved for weight management. Semaglutide, a GLP-1 analog drug approved at a higher dose (2mg) in March for type 2 diabetes, only received approval to treat obesity last year. In the STEP 1 trial, 1,961...
Post
Semaglutide superior to liraglutide for weight loss
(HealthDay)—Among adults with overweight or obesity, once-weekly subcutaneous semaglutide plus counseling for diet and physical activity results in significantly greater weight loss at 68 weeks than once-daily subcutaneous liraglutide, according to a study published in the Jan. 11 issue of the Journal of the American Medical Association. Domenica M. Rubino, M.D., from the Washington Center for...
Post
Semaglutide New Drug Combo Well-Tolerated, Leads to Weight Loss
Becky McCall May 19, 2021 Combining an investigational agent, cagrilintide (Novo Nordisk), with semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, leads to greater weight loss than semaglutide alone in people with a body mass index (BMI) over 27 kg/m2, and the combination was well-tolerated, shows a phase 1 study. The research was presented at the online ECO 2021 meeting by Lone...
Post
Semaglutide found to reduce body weight regardless of patient characteristics
by European Association for the Study of Obesity New research presented at this year’s European Congress on Obesity (held online, 10-13 May) shows that treatment with the drug semaglutide reduces body weight in adults with overweight or obesity, regardless of their baseline characteristics. However, the study showed that female participants had slightly better results than males and also that...
Post
Semaglutide found to be effective against type 2 diabetes
Semaglutide is safe and effective for the treatment of type 2 diabetes, according to a review published online May 13 in Diabetes, Obesity and Metabolism. Panagiotis Andreadis, M.D., from the Aristotle University of Thessaloniki in Greece, and colleagues conducted a systematic literature review to identify randomized controlled trialscomparing semaglutide with placebo or other antidiabetic agents. The primary outcome was...